Multimorbidity guidelines: past, present and future_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Zijun ^1,2,3,4 , SHI Qianling ^2,3,4,5 , GONG Enying ^6,7 , LUO Xufei ^1,2,3 , XUN Yangqin ⁷ , SHAO Ruitai ^6,7 ,  CHEN Yaolong ^1,2,3,4,8

1. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
2. Research Unit of Evidence-based Evaluation and Guidelines, Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
3. Key Laboratory of Evidence Based Medicine of Gansu Province, Lanzhou 730000, P. R. China;
4. Institute of Health Data Science, Lanzhou University, Lanzhou 730000, P. R. China;
5. The First Clinical Medical College, Lanzhou University, Lanzhou 730000, P. R. China;
6. State Key Laboratory of Respiratory Heatth and Multimorbidity, Chinese Academy of Medical Science, Beijing 100005, P. R. China;
7. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, P. R. China;
8. WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou University, Lanzhou 730000, P. R. China;

Corresponding author：

CHEN Yaolong, Email: chevidence@lzu.edu.cn

Keywords：

Multimorbidity; Clinical practice guideline; Guideline development

DOI：

10.7507/1672-2531.202401171

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Multimorbidity is becoming a major issue in global health due to the increased prevalence of chronic diseases and the accelerated aging of the population. Clinical practice guidelines, as key tools for guiding clinical practice, play an important role in the field of multimorbidity, but also face many challenges. In this paper, we will review the necessity of developing multimorbidity guidelines, the current situation, challenges and opportunities, and on this basis, we will put forward our thoughts and suggestions to promote the development of guidelines in the field of multimorbidity in China.

Citation： WANG Zijun, SHI Qianling, GONG Enying, LUO Xufei, XUN Yangqin, SHAO Ruitai, CHEN Yaolong. Multimorbidity guidelines: past, present and future. Chinese Journal of Evidence-Based Medicine, 2024, 24(6): 621-625. doi: 10.7507/1672-2531.202401171 Copy

1.	Van Lerberghe W. The world health report 2008: primary health care: now more than ever. World Health Organization, 2008.
2.
3.
4.
5.
6.
7.	Institute of Medicine. Clinical practice guidelines we can trust. Washington DC: National Academies Press, 2011.
8.	National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management (NICE clinical guideline 56). 2016.
9.
10.
11.	National Institute for Health and Care Research. Multiple long-term conditions (multimorbidity): making sense of the evidence. 2021.
12.
13.	National Institute for Health and Care Excellence. Older people with social care needs and multiple longterm conditions. 2015.
14.	NICE Medicines and Prescribing Centre (UK). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Manchester: National Institute for Health and Care Excellence (NICE), 2015.
15.
16.
17.
18.
19.
20.
21.
22.
23.	中华人民共和国中央人民政府国务院. 《“健康中国2030”规划纲要》. 2016.
24.
25.
26.
27.	Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: an overview of systematic reviews. Ageing Res Rev, 2017, 37: 53-68.
28.	中国医学科学院北京协和医学院. 中国人全生命期共病队列研究(人生队列研究)启动. 2023.
29.
30.
31.

1. Van Lerberghe W. The world health report 2008: primary health care: now more than ever. World Health Organization, 2008.
2.
3.
4.
5.
6.
7. Institute of Medicine. Clinical practice guidelines we can trust. Washington DC: National Academies Press, 2011.
8. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management (NICE clinical guideline 56). 2016.
9.
10.
11. National Institute for Health and Care Research. Multiple long-term conditions (multimorbidity): making sense of the evidence. 2021.
12.
13. National Institute for Health and Care Excellence. Older people with social care needs and multiple longterm conditions. 2015.
14. NICE Medicines and Prescribing Centre (UK). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Manchester: National Institute for Health and Care Excellence (NICE), 2015.
15.
16.
17.
18.
19.
20.
21.
22.
23. 中华人民共和国中央人民政府国务院. 《“健康中国2030”规划纲要》. 2016.
24.
25.
26.
27. Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: an overview of systematic reviews. Ageing Res Rev, 2017, 37: 53-68.
28. 中国医学科学院北京协和医学院. 中国人全生命期共病队列研究(人生队列研究)启动. 2023.
29.
30.
31.

Journal type citation(15)

1.	金名初，贾洪涛，罗茂华，周浴，杨华. 十堰地区引起泌尿系结石的危险因素分析. 现代医学与健康研究电子杂志. 2024(13): 114-116 . Baidu Scholar
2.	李玲玉，李萍，李一帆. 循证护理的饮食营养认知评估在泌尿结石患者中的应用. 齐鲁护理杂志. 2023(10): 119-123 . Baidu Scholar
3.	曹凤娇，白雪娇，侯秀娟. 高尿酸血症合并肾结石中医体质特点和基于LASSO回归的危险因素分析. 中医药导报. 2023(06): 106-110 . Baidu Scholar
4.	刘鎏. 循证护理联合疼痛护理对泌尿系统结石患者术后疼痛及并发症的影响. 医学信息. 2023(19): 167-170 . Baidu Scholar
5.	马双钰，凯买尔丁·阿布都艾尼，陈巍，周晓辉，王玉杰. 老年泌尿系统结石患者的危险因素分析. 新疆医科大学学报. 2022(02): 176-179 . Baidu Scholar
6.	胡赛峰，胡安定，钱挺照，胡春. KIM-1表达水平对高尿酸肾结石患者CR、UREA、GFR、Cys-C的影响. 全科医学临床与教育. 2022(02): 116-118+126 . Baidu Scholar
7.	路玉霞. 基于ODSF的自我管理健康教育视频在泌尿系结石术后双J管留置患者中的护理效果. 山西卫生健康职业学院学报. 2021(01): 100-102 . Baidu Scholar
8.	尹相林，姚嵩坡，李兴洲，沈萍，展秀君，张淑红，白雪，侯庆泽，关宝生，邱洪斌. 痛风和高尿酸血症发病的危险因素. 中国老年学杂志. 2020(10): 2041-2044 . Baidu Scholar
9.	徐媛玉，潘铁军. 泌尿系结石合并高尿酸血症的相关因素及中医证型研究. 华南国防医学杂志. 2020(04): 247-249 . Baidu Scholar
10.	金静，李雪莉. 以循证理论为基础的疼痛护理对泌尿系统结石手术患者术后功能恢复、疼痛程度与睡眠质量的影响. 护理实践与研究. 2020(15): 80-82 . Baidu Scholar
11.	覃天资，黄群. 高尿酸血症与肾非尿酸结石相关研究进展. 右江民族医学院学报. 2019(01): 107-110 . Baidu Scholar
12.	李生辉，柴雪，程庆水，卓栋，宋帅帅，王建帮，程浪，黄后宝. 某院2008—2017年泌尿系结石病例分析. 右江民族医学院学报. 2019(02): 187-189 . Baidu Scholar
13.	宋凌菁，林媛珍，叶帆. 延续护理降低泌尿系结石术后复发率的研究. 实用临床医学. 2018(04): 83-85 . Baidu Scholar
14.	霍振清，罗后宙，梁冰，朱家利，汪溢，姚泽钦. 固肾益气排石协定方对经皮肾镜碎石术后残留结石的治疗效果. 中华中医药学刊. 2018(09): 2277-2280 . Baidu Scholar
15.	申恩瑞，彭惠，陈青，朱静，王冀岚，权彤彤，李玉美，殷水泽，马世武. 停用吡嗪酰胺对初治结核病患者血尿酸水平的影响. 广东医学. 2018(24): 3701-3705 . Baidu Scholar

Other types of references(6)

1.	吴伟璇. 高尿酸血症合并超重/肥胖影响因素分析与体质分布[D]. 广州中医药大学. 2021. Baidu Scholar
2.	申恩瑞. 停用吡嗪酰胺对初治结核病患者血尿酸水平的影响[D]. 南方医科大学. 2019. Baidu Scholar
3.	王欢. 单中心结石相关梗阻性肾病发生与转归的临床研究[D]. 中国人民解放军海军军医大学. 2018. Baidu Scholar
4.	张汉荣，高清河，杨镇有，罗辉. 中国成人泌尿系结石相关危险因素的Meta分析. 中华泌尿外科杂志. 2018(12): 935-939 . Baidu Scholar
5.	范春艳. 泌尿系结石患者健康促进生活方式量表的构建与应用[D]. 苏州大学. 2021. Baidu Scholar
6.	覃天资. 血尿酸水平对肾结石患者尿液KIM-1、NGAL及β2-MG生成的影响[D]. 右江民族医学院. 2019. Baidu Scholar

Next Article
Guideline for the rehabilitation treatment of osteoporosis (2024 edition) ChineseSociety of Physical Medicine and Rehabilitation

Chinese Journal of Evidence-Based Medicine

Multimorbidity guidelines: past, present and future

Abstract Full text Figures/Tables Video References Cited by

Journal type citation(15)

Other types of references(6)

Next Article

Format

Content